Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05874674

The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study

The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Diathesis Undergoing Hemodialysis: A Pilot Study

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
100 (estimated)
Sponsor
Wonju Severance Christian Hospital · Academic / Other
Sex
All
Age
18 Years – 99 Years
Healthy volunteers
Accepted

Summary

Comparison nafamostat and low molecular weight heparin among dialysis patients

Conditions

Interventions

TypeNameDescription
DRUGNafamostat MesylateComparison effect of nafamostat and cnoxan

Timeline

Start date
2023-12-01
Primary completion
2025-12-31
Completion
2026-12-31
First posted
2023-05-25
Last updated
2024-07-30

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT05874674. Inclusion in this directory is not an endorsement.

The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study (NCT05874674) · Clinical Trials Directory